Summary
Dr Reebye is involved in the development of therapeutic gain of function studies using novel RNA activation strategies. His work involves close collaboration with private biotechnology and international academic institutions both in the US and Asia. These versatile and powerful new tools for gene activation has shown an impact in experimental regenerative medicine by redirecting adult stem cells towards a surrogate insulin secreting phenotype and also in oncology by improving liver function and loss of tumour burden in cirrhotic models.
Publications
Journals
Sarker D, Plummer R, Meyer T, et al., 2020, MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase I trial, Clinical Cancer Research, Vol:26, ISSN:1078-0432, Pages:3936-3946
Huang K-W, Reebye V, Czysz K, et al., 2020, Liver Activation of Hepatocellular Nuclear Factor-4 alpha by Small Activating RNA Rescues Dyslipidemia and Improves Metabolic Profile, Molecular Therapy-nucleic Acids, Vol:19, ISSN:2162-2531, Pages:361-370
Conference
Sarker D, Sodergren M, Plummer ER, et al., 2020, Phase Ib dose escalation and cohort expansion study of the novel myeloid differentiating agent MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC)., AMER SOC CLINICAL ONCOLOGY, ISSN:0732-183X
Reebye V, Vasara J, Raulf N, et al., 2020, Therapeutic saRNAstargeting CEBPA in Myeloid Cells. A potential Immunomodulatoryswitch for Anticancer Therapy, 23rd Annual Meeting of the American-Society-for-Gene-and-Cell-Therapy, CELL PRESS, Pages:51-52, ISSN:1525-0016
Sarker D, Sodergren M, Plummer ER, et al., 2020, First-in-human phase I trial of small activating RNA (saRNA) oligonucleotide MTL-CEBPA in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC), Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology, AMER SOC CLINICAL ONCOLOGY, ISSN:0732-183X